Compounds and methods for treating neurological and cardiovascular conditions

Patent metadata

Field	Value
Publication number	US-11484545-B2
Application number	US-202117180469-A
Country	US
Kind code	B2
Filing date	Feb 19, 2021
Priority date	Apr 21, 2016
Publication date	Nov 1, 2022
Grant date	Nov 1, 2022

Abstract

The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

First claim

We claim:

1. A method of treating a disease, disorder, or condition selected from deficit in cognition, deficit in CNS function, deficit in learning, and memory loss, comprising administering to a subject in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof.

2. The method of claim 1 , wherein the disease, disorder, or condition is deficit in cognition.

3. The method of claim 1 , wherein the disease, disorder, or condition is deficit in CNS function.

4. The method of claim 1 , wherein the disease, disorder, or condition is deficit in learning.

5. The method of claim 1 , wherein the disease, disorder, or condition is memory loss.

6. The method of claim 1 , wherein the subject has suffered one or more traumatic brain injuries (TBI or TBIs) and the disease, disorder, or condition is associated with the TBI or TBIs.

7. The method of claim 1 , wherein the subject has suffered one or more strokes and the disease, disorder, or condition is associated with the one or more strokes.

8. The method of claim 7 , wherein the subject has suffered one or more ischemic strokes, hemorrhagic strokes, subarachnoid hemorrhages, cerebral vasospasms, or transient ischemic attacks (TIA).

9. The method of claim 1 , wherein the subject has Alzheimer's disease and the disease, disorder, or condition is associated with the Alzheimer's disease.

10. The method of claim 1 , wherein the method improves cognitive or neurological function as measured by a score increase between about 1% and 20% in the delayed verbal recall task of the revised Wechsler Memory Scale.

11. The method of claim 10 , wherein the method provides a score increase between about 1% and 10% in the delayed verbal recall task of the revised Wechsler Memory Scale.

12. The method of claim 1 , wherein the method increases synaptic plasticity, improves hippocampal long-term potentiation, improves cognitive function, decreases cognitive impairment, and/or improves or restores memory or learning.

13. The method of claim 9 , wherein the method increases synaptic plasticity, improves hippocampal long-term potentiation, improves cognitive function, decreases cognitive impairment, prevents or delays cognitive decline, decreases plaque burden, enhances beta amyloid clearance, and/or improves or restores memory or learning.

14. The method of claim 2 , wherein the method improves or enhances cognition or neurological function by enhancing synaptogenesis.

15. A method of improving cognitive or neurological function in a subject having Alzheimer's disease, comprising administering to a subject in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof; wherein the improvement in cognitive or neurological function as measured by a score increase between about 1% and 20% in the delayed verbal recall task of the revised Wechsler Memory Scale.

16. A method of treating pain, comprising administering to a subject in need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable composition thereof.

17. The method of claim 16 , wherein the pain is neuropathic pain.

18. The method of claim 16 , wherein the pain is inflammatory pain.

19. The method of claim 16 , wherein the pain is acute pain.

20. The method of claim 16 , wherein the pain is chronic pain.

21. The method of claim 16 , wherein the pain is nociceptive pain.

22. The method of claim 16 , wherein the pain is non-inflammatory musculoskeletal pain, fibromyalgia syndrome (FMS), or myofascial pain syndrome (MPS).

23. The method of claim 16 , wherein the pain is selected from musculoskeletal pain, fibromyalgia, myofascial pain, pain during menstruation, pain during osteoarthritis, pain during rheumatoid arthritis, pain during gastrointestinal inflammation, pain during inflammation of the heart muscle, pain during multiple sclerosis, pain during neuritis, pain during AIDS, pain during chemotherapy, tumor pain, headache, chronic pain syndrome (CPS), central pain, trigeminal neuralgia, shingles, stamp pain, phantom limb pain, temporomandibular joint disorder, nerve injury, migraine, post-herpetic neuralgia, neuropathic pain encountered as a consequence of injuries, amputation infections, metabolic disorders or degenerative diseases of the nervous system, neuropathic pain associated with diabetes, pseudesthesia, hypothyroidism, uremia, vitamin deficiencies or alcoholism, acute pain after injuries, postoperative pain, pain during acute gout, and pain from an operation.

24. The method of claim 23 , wherein the musculoskeletal pain is neck and shoulder pain and/or spasms, back pain, sciatica, chest ache, or thigh muscle ache.

25. The method of claim 16 , wherein the pain is, or is associated with, otitis externa (OE), otitis media (OM), mastoiditis, bullous myringitis, eustachian tubal catarrh, labyrinthitis, facial nerve neuritis, temporal bone osteoradionecrosis, mal de debarquement, temporal bone fracture, or temporomandibular joint disease.

Assignees

• Astrocyte Pharmaceuticals Inc
• Univ Texas

Inventors

• Korinek William S
• Lechleiter James D
• Liston Theodore E

Classifications

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title